NASDAQ:TNXPTonix Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.70 -0.03 (-4.11 %) (As of 04/8/2020 05:34 AM ET) Add Compare Share Today's Range$0.69Now: $0.70▼$0.7450-Day Range$0.40MA: $0.78▼$1.7352-Week Range$0.39Now: $0.70▼$27.50Volume1.70 million shsAverage Volume9.39 million shsMarket Capitalization$34.55 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.30, Tonix Pharmaceuticals has a potential upside of 85.7% from its current price of $0.70.Amount of Analyst CoverageTonix Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesTonix Pharmaceuticals has received 321 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTonix Pharmaceuticals has received 249 “underperform” votes. (Add your “underperform” vote.)Community SentimentTonix Pharmaceuticals has received 56.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote “Outperform” if you believe TNXP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.15% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 0.73% of the stock of Tonix Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to decrease by -100.00% in the coming year, from ($2.49) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNXP Previous Symbol CUSIPN/A CIK1430306 Webhttp://www.tonixpharma.com/ Phone212-980-9155Debt Debt-to-Equity RatioN/A Current Ratio2.72 Quick Ratio2.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.11 per share Price / Book0.63Profitability EPS (Most Recent Fiscal Year)($19.33) Net Income$-28,620,000.00 Net MarginsN/A Return on Equity-229.38% Return on Assets-185.05%Miscellaneous Employees12 Outstanding Shares49,353,000Market Cap$34.55 million Next Earnings Date5/11/2020 (Estimated) OptionableOptionable Receive TNXP News and Ratings via Email Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TNXP Rates by TradingView Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions How has Tonix Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TNXP shares have decreased by 15.8% and is now trading at $0.70. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tonix Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tonix Pharmaceuticals. When is Tonix Pharmaceuticals' next earnings date? Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Tonix Pharmaceuticals. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced its quarterly earnings results on Tuesday, March, 24th. The company reported ($2.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.49) by $1.37. View Tonix Pharmaceuticals' earnings history. When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work? Tonix Pharmaceuticals's stock reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for TNXP? 1 brokerages have issued 1 year target prices for Tonix Pharmaceuticals' shares. Their forecasts range from $1.30 to $1.30. On average, they anticipate Tonix Pharmaceuticals' share price to reach $1.30 in the next twelve months. This suggests a possible upside of 85.7% from the stock's current price. View analysts' price targets for Tonix Pharmaceuticals. Has Tonix Pharmaceuticals been receiving favorable news coverage? Press coverage about TNXP stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutTonix Pharmaceuticals. Are investors shorting Tonix Pharmaceuticals? Tonix Pharmaceuticals saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 1,856,900 shares, a decrease of 43.6% from the February 27th total of 3,290,000 shares. Based on an average daily volume of 9,104,100 shares, the days-to-cover ratio is presently 0.2 days. Approximately 21.8% of the shares of the company are short sold. View Tonix Pharmaceuticals' Current Options Chain. Who are some of Tonix Pharmaceuticals' key competitors? Some companies that are related to Tonix Pharmaceuticals include Chiasma (CHMA), Affimed (AFMD), Kezar Life Sciences (KZR), Kalvista Pharmaceuticals (KALV), TAIWAN LIPOSOME/S (TLC), Tyme Technologies (TYME), Kindred Biosciences (KIN), MediciNova (MNOV), REDHILL BIOPHAR/S (RDHL), Aeglea Bio Therapeutics (AGLE), Newron Pharmaceuticals (NWPHF), Marinus Pharmaceuticals (MRNS), Cerecor (CERC), BIOFRONTERA AG/ADR (BFRA) and Endonovo Therapeutics (ENDV). What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX), T2 Biosystems (TTOO), Ibio (IBIO), Onconova Therapeutics (ONTX), Opko Health (OPK), Vaxart (VXRT) and Actinium Pharmaceuticals (ATNM). Who are Tonix Pharmaceuticals' key executives? Tonix Pharmaceuticals' management team includes the following people: Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)Mr. Bradley Saenger, CFO & Treasurer (Age 45)Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)Mrs. Jessica Edgar Morris, Chief Operating OfficerDr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel. What is Tonix Pharmaceuticals' stock symbol? Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP." How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tonix Pharmaceuticals' stock price today? One share of TNXP stock can currently be purchased for approximately $0.70. How big of a company is Tonix Pharmaceuticals? Tonix Pharmaceuticals has a market capitalization of $34.55 million. The company earns $-28,620,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe. View additional information about Tonix Pharmaceuticals. What is Tonix Pharmaceuticals' official website? The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/. How can I contact Tonix Pharmaceuticals? Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: The Role of a Fiduciary and Individual Investors
